Study details
Enrolling now
Orexin Receptor Antagonism for Alcohol Use Disorder
Ohio State University
NCT IDNCT07214207ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
250
Study length
about 4.8 years
Ages
18–65
Locations
1 site in OH
About this study
Researchers are testing if suvorexant, a drug that blocks orexin receptors, can help people with alcohol use disorder. The trial will compare suvorexant to a placebo (a fake pill) over 8 weeks to see if suvorexant reduces alcohol cravings and stress-related drinking.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Suvorexant 10 mg
PhasePhase 2
DrugSuvorexant 10 mg
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
suvorexant
Drug routes
oral (Oral Tablet)
Body systems
Psychiatry / Mental Health